Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer
00:01 EDT 2 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Bristol-Myers
Squibb Company (NYSE: BMY) today announced interim results from the
expanded Phase 1 dose-ranging study 003 (n=296) of its investigational
anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in
...
Other Sources for this Article
Bristol-Myers Squibb
Media: Sarah Koenig, 609-252-4145, sarah.koenig@bms.com
Investors:
John Elicker, 609-252-4611, john.elicker@bms.com
More From BioPortfolio on "Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
